文献速递心外重症与机械循环支持

胸骨保留技术植入全磁悬浮左心室辅助装置的初步经验

Implantation of a fully magnetically levitated left ventricular assist device using a sternal-sparing surgical technique.
PubMed 文献 · J Heart Lung Transplant · 2019-09-25

该单中心回顾性研究纳入2015年9月至2018年9月连续植入HeartMate 3左心室辅助装置的105例患者,比较胸骨保留(SS)与传统胸骨切开(TS)两种手术方式。SS组41例(39%),TS组64例(61%)。SS组严重右心衰竭发生率显著更低(7% vs 28%,p=0.012),输血更少(41% vs 86%,p<0.001),住院时间更短(15.5 vs 21天,p=0.018),6个月生存率93%。结论认为SS技术在选择合适的患者中安全有效。

要点

  • SS技术植入HM3 LVAD无术中转开胸,严重右心衰竭发生率更低(7% vs 28%)。
  • SS组输血比例更低(41% vs 86%),住院时间更短(15.5 vs 21天)。
  • SS组6个月生存率93%,但需进一步研究确认获益。

核心结论

  • 在单中心观察性研究中,胸骨保留技术可能为选择合适患者植入HeartMate 3左心室辅助装置的安全有效手术方式。
  • 与常规胸骨切开相比,胸骨保留技术的潜在获益需进一步研究。

研究设计与样本

  • 回顾性单中心研究,纳入2015年9月至2018年9月连续植入HeartMate 3左心室辅助装置的105例患者。
  • 按手术方式分为胸骨保留组(41例,39%)和传统胸骨切开组(64例,61%)。

主要发现

  • 胸骨保留组严重右心衰竭发生率显著低于传统胸骨切开组(7% vs 28%,p=0.012)。
  • 胸骨保留组输血比例显著更低(41% vs 86%,p<0.001)。
  • 胸骨保留组住院时间显著更短(15.5 vs 21天,p=0.018)。
  • 胸骨保留组6个月生存率为93%。
  • 胸骨保留组患者更年轻,其余特征两组相似,无术中转开胸。

临床怎么用

  • 对于经过选择的晚期心力衰竭患者,可考虑采用胸骨保留技术植入HeartMate 3左心室辅助装置。
  • 胸骨保留技术可能减少严重右心衰竭、输血需求和住院时间,但需进一步验证。

局限性

  • 本研究为单中心回顾性观察性研究,样本量有限。
  • 胸骨保留组患者更年轻,可能存在选择偏倚。
  • 胸骨保留技术相比传统胸骨切开的潜在获益尚需进一步研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Left ventricular assist devices (LVADs) have improved outcomes for selected patients with advanced heart failure, but alternative optimal surgical techniques remain to be defined. We aim to describe our initial experience in using a sternal-sparing (SS) technique for implantation of a magnetically levitated LVAD, the HeartMate 3 (HM3) pump. METHODS: This retrospective, single-center study included consecutive patients implanted with the HM3 LVAD between September 2015 and September 2018. Patients were compared based on surgical approach: SS or traditional sternotomy (TS). The primary outcome was overall survival at 6 months. Secondary outcomes included peri-operative complications, blood product utilization, and hospital readmissions. RESULTS: Of 105 patients implanted with the HM3 LVAD, 41 (39%) were implanted via SS and 64 (61%) via TS approach. There were no intraoperative conversions. The SS patients were younger; otherwise, all other characteristics were similar between cohorts. The SS cohort demonstrated a significantly lower incidence of severe right ventricular failure (7% vs 28%, p = 0.012), fewer blood-product transfusions (41% vs 86%, p < 0.001), and shorter index hospital length of stay (15.5 vs 21 days, p = 0.018). Six-month survival was 93% for the SS cohort. CONCLUSIONS: In this single-center observational study, we have demonstrated that the SS approach may be a safe and effective surgical technique for implantation of the HM3 LVAD in well-selected patients. The potential benefits compared with TS require further inquiry.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Gosev I, Wood K, Ayers B, et al. Implantation of a fully magnetically levitated left ventricular assist device using a sternal-sparing surgical technique. J Heart Lung Transplant. 2019. PMID: 31636043. doi:10.1016/j.healun.2019.09.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。